Escape mutations in NS4B render dengue virus insensitive to the antiviral activity of the paracetamol metabolite AM404

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 2554-2557

  Van Cleef, Koen W R ^a   Overheul, Gijs J ^a   Thomassen, Michael C ^a   Marjakangas, Jenni M ^a   Van Rij, Ronald P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NONSTRUCTURAL PROTEIN 4B; PARACETAMOL; RIBAVIRIN; ANTIVIRUS AGENT; ARACHIDONIC ACID DERIVATIVE; LUCIFERASE; N-(4-HYDROXYPHENYL)ARACHIDONYLAMIDE; NALTREXONE; NS4B PROTEIN, FLAVIVIRUS; SDM 25N; VIRAL PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; DENGUE VIRUS; DOSE RESPONSE; GENE MUTATION; HELA CELL LINE; HUMAN; HUMAN CELL; PLEIOTROPY; PRIORITY JOURNAL; REPLICON CELL; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; BIOTRANSFORMATION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; MUTATION; REPORTER GENE;

ACETAMINOPHEN; ANTIVIRAL AGENTS; ARACHIDONIC ACIDS; BIOTRANSFORMATION; DENGUE VIRUS; DRUG RESISTANCE, MULTIPLE, VIRAL; GENE EXPRESSION; GENES, REPORTER; HELA CELLS; HUMANS; LUCIFERASES; MICROBIAL SENSITIVITY TESTS; MUTATION; NALTREXONE; RIBAVIRIN; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84963783160     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02462-15     Document Type: Article

References (35)

1. World Health Organization. 2009. Dengue: guidelines for diagnosis, treatment, prevention and control, new edition. WHO Press, Geneva, Switzerland.
2. Guzman A, Isturiz RE. 2010. Update on the global spread of dengue. Int J Antimicrob Agents 36(Suppl 1):S40-S42. http://dx.doi.org/10.1016/j.ijantimicag.2010.06.018.
3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507. http://dx.doi.org/10.1038/nature12060.
4. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, Moyes CL, Farlow AW, Scott TW, Hay SI. 2012. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 6:e1760. http://dx.doi.org/10.1371/journal.pntd.0001760.
5. Franco C, Hynes NA, Bouri N, Henderson DA. 2010. The dengue threat to the United States. Biosecur Bioterror 8:273-276. http://dx.doi.org/10.1089/bsp. 2010.0032.
6. La Ruche G, Souares Y, Armengaud A, Peloux-Petiot F, Delaunay P, Despres P, Lenglet A, Jourdain F, Leparc-Goffart I, Charlet F, Ollier L, Mantey K, Mollet T, Fournier JP, Torrents R, Leitmeyer K, Hilairet P, Zeller H, Van Bortel W, Dejour-Salamanca D, Grandadam M, Gastellu-Etchegorry M. 2010. First two autochthonous dengue virus infections in metropolitan France, September 2010. Euro Surveill 15(39): pii=19676. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19676.
7. Gjenero-Margan I, Aleraj B, Krajcar D, Lesnikar V, Klobucar A, Pem-Novosel I, Kurecic-Filipovic S, Komparak S, Martic R, Duricic S, Betica-Radic L, Okmadzic J, Vilibic-Cavlek T, Babic-Erceg A, Turkovic B, Avsic-Zupanc T, Radic I, Ljubic M, Sarac K, Benic N, Mlinaric-Galinovic G. 2011. Autochthonous dengue fever in Croatia, August-September 2010. Euro Surveill 16(9): pii=19805. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19805.
8. Hemingway J. 2014. The role of vector control in stopping the transmission of malaria: threats and opportunities. Philos Trans R Soc Lond B Biol Sci 369:20130431. http://dx.doi.org/10.1098/rstb.2013.0431.
9. Hemingway J, Beaty BJ, Rowland M, Scott TW, Sharp BL. 2006. The Innovative Vector Control Consortium: improved control of mosquitoborne diseases. Trends Parasitol 22:308-312. http://dx.doi.org/10.1016/j.pt.2006.05.003.
10. Hemingway J, Hawkes NJ, McCarroll L, Ranson H. 2004. The molecular basis of insecticide resistance in mosquitoes. Insect Biochem Mol Biol 34:653-665. http://dx.doi.org/10.1016/j.ibmb.2004.03.018.
11. van Cleef KW, Overheul GJ, Thomassen MC, Kaptein SJ, Davidson AD, Jacobs M, Neyts J, van Kuppeveld FJ, van Rij RP. 2013. Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication. Antiviral Res 99:165-171. http://dx.doi.org/10.1016/j.antiviral.2013.05.011.
12. Kaptein SJ, De Burghgraeve T, Froeyen M, Pastorino B, Alen MM, Mondotte JA, Herdewijn P, Jacobs M, de Lamballerie X, Schols D, Gamarnik AV, Sztaricskai F, Neyts J. 2010. A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro. Antimicrob Agents Chemother 54:5269-5280. http://dx.doi.org/10.1128/AAC.00686-10.
13. Hogestatt ED, Jonsson BA, Ermund A, Andersson DA, Bjork H, Alexander JP, Cravatt BF, Basbaum AI, Zygmunt PM. 2005. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 280:31405-31412. http://dx.doi.org/10.1074/jbc. M501489200.
14. Mallet C, Barriere DA, Ermund A, Jonsson BA, Eschalier A, Zygmunt PM, Hogestatt ED. 2010. TRPV1 in brain is involved in acetaminopheninduced antinociception. PLoS One 5(9):e12748. http://dx.doi.org/10.1371/journal.pone.0012748.
15. Takhampunya R, Ubol S, Houng HS, Cameron CE, Padmanabhan R. 2006. Inhibition of dengue virus replication by mycophenolic acid and ribavirin. J Gen Virol 87:1947-1952. http://dx.doi.org/10.1099/vir.0.81655-0.
16. Diamond MS, Zachariah M, Harris E. 2002. Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology 304:211-221. http://dx.doi.org/10.1006/viro.2002.1685.
17. Huang YH, Lei HY, Liu HS, Lin YS, Liu CC, Yeh TM. 2000. Dengue virus infects human endothelial cells and induces IL-6 and IL-8 production. Am J Trop Med Hyg 63:71-75.
18. Wang QY, Dong H, Zou B, Karuna R, Wan KF, Zou J, Susila A, Yip A, Shan C, Yeo KL, Xu H, Ding M, Chan WL, Gu F, Seah PG, Liu W, Lakshminarayana SB, Kang C, Lescar J, Blasco F, Smith PW, Shi PY. 2015. Discovery of dengue virus NS4B inhibitors. J Virol 89:8233-8244. http://dx.doi.org/10.1128/JVI.00855-15.
19. Huang CY, Butrapet S, Pierro DJ, Chang GJ, Hunt AR, Bhamarapravati N, Gubler DJ, Kinney RM. 2000. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 74:3020-3028. http://dx.doi.org/10.1128/JVI.74.7.3020-3028.2000.
20. Halstead SB, Diwan AR, Marchette NJ, Palumbo NE, Srisukonth L. 1984. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. I. Attributes of uncloned virus at different passage levels. Am J Trop Med Hyg 33:654-665.
21. Alvarez DE, De Lella Ezcurra AL, Fucito S, Gamarnik AV. 2005. Role of RNA structures present at the 3'UTR of dengue virus on translation, RNA synthesis, and viral replication. Virology 339:200-212. http://dx.doi.org/10.1016/j.virol. 2005.06.009.
22. Xie X, Wang QY, Xu HY, Qing M, Kramer L, Yuan Z, Shi PY. 2011. Inhibition of dengue virus by targeting viral NS4B protein. J Virol 85:11183-11195. http://dx.doi.org/10.1128/JVI.05468-11.
23. Ottani A, Leone S, Sandrini M, Ferrari A, Bertolini A. 2006. The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur J Pharmacol 531:280-281. http://dx.doi.org/10.1016/j.ejphar.2005.12.015.
24. Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S. 2006. Paracetamol: new vistas of an old drug. CNS Drug Rev 12:250-275. http://dx.doi.org/10.1111/j.1527-3458.2006.00250.x.
25. Caballero FJ, Soler-Torronteras R, Lara-Chica M, Garcia V, Fiebich BL, Munoz E, Calzado MA. 2015. AM404 inhibits NFAT and NF-κB signaling pathways and impairs migration and invasiveness of neuroblastoma cells. Eur J Pharmacol 746:221-232. http://dx.doi.org/10.1016/j.ejphar.2014.11.023.
26. Feeney ER, Chung RT. 2014. Antiviral treatment of hepatitis C. BMJ 348:g3308.
27. Looney D, Ma A, Johns S. 2015. HIV therapy: the state of art. Curr Top Microbiol Immunol 389:1-29.
28. Webster DP, Klenerman P, Dusheiko GM. 2015. Hepatitis C. Lancet 385:1124-1135. http://dx.doi.org/10.1016/S0140-6736 (14) 62401-6.
29. Lou Z, Sun Y, Rao Z. 2014. Current progress in antiviral strategies. Trends Pharmacol Sci 35:86-102. http://dx.doi.org/10.1016/j.tips.2013.11.006.
30. Sayce AC, Miller JL, Zitzmann N. 2010. Targeting a host process as an antiviral approach against dengue virus. Trends Microbiol 18:323-330. http://dx.doi.org/10.1016/j.tim.2010.04.003.
31. Lim SP, Wang QY, Noble CG, Chen YL, Dong H, Zou B, Yokokawa F, Nilar S, Smith P, Beer D, Lescar J, Shi PY. 2013. Ten years of dengue drug discovery: progress and prospects. Antiviral Res 100:500-519. http://dx.doi.org/10.1016/j.antiviral.2013.09.013.
32. Patkar CG, Larsen M, Owston M, Smith JL, Kuhn RJ. 2009. Identification of inhibitors of yellow fever virus replication using a replicon-based high-throughput assay. Antimicrob Agents Chemother 53:4103-4114. http://dx.doi.org/10.1128/AAC.00074-09.
33. Xie X, Zou J, Wang QY, Shi PY. 2015. Targeting dengue virus NS4B protein for drug discovery. Antiviral Res 118:39-45. http://dx.doi.org/10.1016/j.antiviral.2015.03.007.
34. Miller S, Sparacio S, Bartenschlager R. 2006. Subcellular localization and membrane topology of the dengue virus type 2 non-structural protein 4B. J Biol Chem 281:8854-8863. http://dx.doi.org/10.1074/jbc. M512697200.
35. Li Y, Kim YM, Zou J, Wang QY, Gayen S, Wong YL, Lee le T, Xie X, Huang Q, Lescar J, Shi PY, Kang C. 2015. Secondary structure and membrane topology of dengue virus NS4B N-terminal 125 amino acids. Biochim Biophys Acta 1848:3150-3157. http://dx.doi.org/10.1016/j.bbamem.2015.09.016.